Fennec Pharmaceuticals
FENC
65 hedge funds and large institutions have $161M invested in Fennec Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 5 closing their positions.
49,100% more call options, than puts
Call options by funds: $492K | Put options by funds: $1K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
16% more funds holding
Funds holding: 56 → 65 (+9)
4% less capital invested
Capital invested by funds: $168M → $161M (-$7.32M)
2.77% less ownership
Funds ownership: 56.35% → 53.58% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
+$4.38M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.42M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.45M |
| 4 |
Renaissance Technologies
New York
|
+$1.4M |
| 5 |
LPC
Lion Point Capital
New York
|
+$602K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$13.5M |
| 2 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$2.69M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.32M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.27M |
| 5 |
6CM
683 Capital Management
New York
|
-$923K |
FENC Hedge Fund Activity: Q1 2024 in Review
65 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2024, worth a combined $161M — down 4.3% from $168M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new FENC positions and 5 closed out — a net gain of 9 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was DG Capital Management, adding an estimated $4.38M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $13.5M sold.
- 65 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2024, up from 56 in Q4 2023.
- Funds reported $161M of Fennec Pharmaceuticals stock for Q1 2024, down 4.3% quarter-over-quarter.
- 14 funds opened new Fennec Pharmaceuticals positions in Q1 2024 and 5 closed out, a net change of +9 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2024 was DG Capital Management, an estimated $4.38M added.
- The largest Fennec Pharmaceuticals seller in Q1 2024 was Avoro Capital Advisors, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2024.